ADAG stock forecast, quote, news & analysis
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies... Show more
Adagene (ADAG) Stock Analysis: Muzastotug Catalysts and an Extended Cash Runway
Key Takeaways
- ADAG trades near $3.40, down roughly 9% over the trailing month and range-bound between about $3.20 and $4.25 since mid-August 2026.
- Six-month 2026 results reported in August showed cash and equivalents of about $127.9 million and a runway extended into late 2028.
- Lead candidate muzastotug (ADG126) has generated encouraging efficacy and safety data in microsatellite-stable colorectal cancer, with randomized Phase 2 results expected in the first half of 2027.
- Partnerships with Sanofi, Exelixis, and Incyte continue to validate the company's SAFEbody precision-masking platform.
- Analyst firms have recently reaffirmed or initiated Buy ratings with price targets of $8 and $9.
Current Market Snapshot
Adagene Inc. (ADAG) shares have traded in a relatively contained range in recent weeks. The stock has pulled back approximately 9% over the trailing month, moving from a close near $3.72 in mid-August to roughly $3.40, and remains well above its 52-week low near $1.30 while sitting below the 52-week high of about $4.85. With a market capitalization of roughly $230 million, ADAG is a thinly traded, clinical-stage name whose share price can swing meaningfully on clinical data updates and sector-wide biotech sentiment.
Adagene (ADAG) Business Overview and Competitive Position
Adagene is a platform-driven, clinical-stage biotechnology company focused on discovering and developing novel antibody-based cancer immunotherapies. The company combines computational biology and artificial intelligence with its proprietary Dynamic Precision Library (DPL) platform, which is built around NEObody, SAFEbody, and POWERbody technologies. Its signature SAFEbody precision-masking approach is designed to shield an antibody's binding domain until it reaches the tumor microenvironment, reducing on-target, off-tumor toxicity in healthy tissue.
The company's lead program, muzastotug (ADG126), is a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 on regulatory T cells. It is being evaluated in Phase 1b/2 and Phase 2 studies in combination with anti-PD-1 therapy, with a primary focus on microsatellite-stable (MSS) metastatic colorectal cancer. Adagene is headquartered in Suzhou, China, and its platform has been validated through collaborations with large pharmaceutical partners including Sanofi (SNY), Exelixis (EXEL), and Incyte (INCY).
Recent Developments Driving ADAG
Adagene reported its six-month 2026 financial results in mid-August, disclosing cash and equivalents of approximately $127.9 million as of June 30, 2026, and an extended cash runway into late 2028 following an April 2026 equity financing. The update also highlighted clinical progress for muzastotug in combination with Merck's (MRK) Keytruda (pembrolizumab) in MSS colorectal cancer patients without liver metastases. In the combined 20 mg/kg dose cohort, the confirmed objective response rate reached 31% with a median progression-free survival of 6.7 months, while a 20 mg/kg loading-dose cohort reported a 36% objective response rate and median progression-free survival of 15.4 months. Across 67 patients, the discontinuation rate was only 4%, with no dose-limiting toxicities reported.
The company also presented triple-combination data at the AACR annual meeting covering first-line hepatocellular carcinoma and late-line MSS colorectal cancer, and it announced that Sanofi's global Phase 1/2 basket trial evaluating muzastotug with a next-generation immuno-oncology agent had dosed its first patients. A separate clinical collaboration with Incyte to evaluate muzastotug with INCA33890 was also disclosed. Additionally, Adagene appointed Peter Lebowitz, a former Global Head of Oncology R&D at Johnson & Johnson, to its Scientific and Strategic Advisory Board. Following the update, LifeSci Capital reaffirmed a Buy rating with an $8 price target, while Chardan Capital initiated coverage with a Buy rating and a $9 target.
Trending AI Robots
For traders seeking a data-driven complement to fundamental research, Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing automated trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers across the market, but only the most relevant and highest-performing bots appear in this featured section. Each bot operates with its own strategy, timeframe, and performance metrics, allowing users to compare approaches that range from short-term momentum signals to longer-horizon trend models. Exploring the section can help investors understand how quantitative, AI-driven tools approach names like Adagene alongside the broader market.
2026 Outlook and What Investors Should Watch
Adagene's investment narrative into 2026 and 2027 centers on clinical execution and platform monetization. The most important near-term catalyst is the randomized Phase 2 dose-optimization study of muzastotug in MSS colorectal cancer, with results expected in the first half of 2027 and a potential registrational trial targeted to begin in 2027. Investors should also monitor the investigator-initiated neoadjuvant Phase 2 trial in colorectal cancer, additional data from the Sanofi-sponsored basket study, and the planned Incyte combination trial.
On the financial side, the extended cash runway reduces near-term dilution risk but does not eliminate it, as a clinical-stage biotech without approved products still depends on future financings or partnerships. Macroeconomic conditions, biotech sector risk appetite, and regulatory decisions remain additional factors that can influence the stock. Competitive developments in the next-generation CTLA-4 and antibody-masking space should also be watched closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ADAG in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 15, 2026
ADAG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 46 of 51 cases where ADAG's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ADAG's RSI Indicator exited the oversold zone, 20 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +13.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADAG advanced for three days, in 178 of 211 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADAG as a result. In 89 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ADAG turned negative on August 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
ADAG moved below its 50-day moving average on August 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ADAG crossed bearishly below the 50-day moving average on September 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADAG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ADAG entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.237) is normal, around the industry mean (26.565). P/E Ratio (0.000) is within average values for comparable stocks, (41.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.024). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (17.606) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ADAG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADAG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology